ValuEngine upgraded shares of VIVUS (NASDAQ:VVUS) from a strong sell rating to a sell rating in a research note released on Friday morning.

Separately, Zacks Investment Research cut VIVUS from a buy rating to a hold rating in a research note on Saturday, January 6th.

VIVUS (NASDAQ:VVUS) opened at $0.41 on Friday. VIVUS has a 52 week low of $0.40 and a 52 week high of $1.38. The stock has a market capitalization of $43.06, a price-to-earnings ratio of 1.23 and a beta of 0.69. The company has a quick ratio of 7.09, a current ratio of 7.47 and a debt-to-equity ratio of 643.86.

VIVUS (NASDAQ:VVUS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The company had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $16.00 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. research analysts expect that VIVUS will post -0.32 EPS for the current year.

Several large investors have recently added to or reduced their stakes in VVUS. Creative Planning grew its stake in shares of VIVUS by 1,691.3% in the fourth quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 346,235 shares in the last quarter. OxFORD Asset Management LLP grew its stake in shares of VIVUS by 58.2% in the second quarter. OxFORD Asset Management LLP now owns 929,511 shares of the biopharmaceutical company’s stock worth $1,134,000 after purchasing an additional 341,976 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in VIVUS by 166.2% during the third quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 246,927 shares in the last quarter. Macquarie Group Ltd. bought a new position in VIVUS during the third quarter valued at about $192,000. Finally, Northern Trust Corp boosted its stake in VIVUS by 16.8% during the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 39,473 shares in the last quarter. 31.44% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/05/vivus-vvus-upgraded-by-valuengine-to-sell.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.